Every approved drug is on a one-way ratchet toward first-line use.
Once a mechanism proves itself, each new trial widens the label rather than defends it — sotatercept now carries a third Phase 3 trial covering newly diagnosed PAH with same-month guideline recognition, and Inluriyo converted to a full, all-oral combination approval within a year of launch, pushing day-one drugs toward universal early use.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Pirtobrutinib jumps from its relapsed/refractory foothold directly into previously untreated CLL, pulling a new mechanism to the frontline at first approval.
Within a year of launch the monotherapy graduated into a full all-oral combination approval — the label ratcheting wider, never narrower.
Each successive Phase 3 pushes the label from refractory patients toward the newly diagnosed — the one-way ratchet toward first-line use, with same-month guideline recognition.
Checkpoint blockade moves into the curative-intent post-surgical setting to halve recurrence risk, widening the label toward universal early use rather than defending a metastatic foothold.
Tukysa leaps from later-line salvage settings straight into first-line maintenance, ratcheting the franchise toward day-one use.